Side-by-side · Research reference
MazdutidevsSS-31
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED19/62 cited
BPhase 3HUMAN-REVIEWED9/43 cited
Mazdutide
GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3
SQ · Abdomen · Once WeeklyJi 2026
SS-31
Cardiolipin-binding · Mitochondrial protective
SQ · Abdomen · Once daily
01Mechanism of Action
Parameter
Mazdutide
SS-31
Primary target
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Cardiolipin in inner mitochondrial membraneSzeto 2014
Pathway
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014Szilagyi 2009
Downstream effect
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014
Feedback intact?
Yes — physiological receptor-mediated signaling preserved
—
Origin
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014
Antibody development
—
—
02Dosage Protocols
Parameter
Mazdutide
SS-31
Phase 2 studied dose
—
Dose escalation
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
—
Evidence basis
Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014Szilagyi 2009
Duration (trials)
24–48 weeks
—
Population
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
—
Standard dose
—
40 mg / day SQ (clinical trials)Szeto 2014
Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.
Lower / starter dose
—
5 mg / day (anecdotal)
Duration
—
Indefinite for mitochondrial disease; cycled for healthspan use
Reconstitution
—
Bacteriostatic water
Timing
—
Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress
Half-life
—
~3 h plasma; tissue uptake longer
03Metabolic / Fat Loss Evidence
Parameter
Mazdutide
SS-31
Percentage body weight loss
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
—
Responder rate (≥10% loss)
Not explicitly reported in available abstracts
—
Visceral fat
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
—
Glycemic improvement
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
—
Key publications
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
—
04Side Effects & Safety
Parameter
Mazdutide
SS-31
Gastrointestinal symptoms
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
—
Injection site reactions
Erythema, pruritus, local discomfort
—
Hypoglycemia
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
—
Cardiovascular effects
Increased heart rate (glucagon effect, transient)
—
Pancreatitis risk
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
—
Thyroid C-cell tumors
Black box warning for GLP-1 class (rodent data); human relevance unclear
—
Gallbladder disease
Cholelithiasis, cholecystitis (rapid weight loss effect)
—
Tolerability
Generally well-tolerated; GI effects diminish with dose titration
—
Injection site reaction
—
Erythema, mild pruritus
GI symptoms
—
Nausea (uncommon)
Headache
—
Reported in some Phase 3 trials
Cardiovascular
—
Cardio-protective in studies; no signal of harm
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
SS-31
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
SS-31
- ·None established
05Administration Protocol
Parameter
Mazdutide
SS-31
1. Preparation
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
Add bacteriostatic water per label. Light-protected handling.
2. Injection site
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
Morning fasted; pre-workout for exercise-augmented mitochondrial stress.
4. Storage
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle technique
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Mazdutide
— no documented stacks
SS-31
+ MOTS-c
ModerateSS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.
- SS-31
- 5–10 mg SQ · daily morning
- MOTS-c
- 5 mg SQ · 2× per week pre-workout
- Primary benefit
- Mitochondrial preservation + biogenesis